Instil Bio, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TIL$6.35-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $5,801 | $8,805 |
| Restricted cash | 280 | 1,830 |
| Marketable securities | 73,867 | 104,510 |
| Prepaid expenses and other current assets | 4,220 | 9,325 |
| Assets held for sale | 112,096 | — |
| Total current assets | 196,264 | 124,470 |
| Property, plant and equipment, net | 138 | 129,406 |
| Operating lease right-of-use assets | 415 | 934 |
| Long-term investments | 3,444 | — |
| Accrued rent receivable | 7,360 | 4,267 |
| Other long-term assets | 4,147 | 4,490 |
| Total assets | $211,768 | $263,567 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $928 | $659 |
| Accrued expenses and other current liabilities | 4,769 | 7,237 |
| Total current liabilities | 5,697 | 7,896 |
| Contingent consideration | 948 | 948 |
| Operating lease liabilities, non-current | — | 1,017 |
| Loan payable | 84,613 | 84,187 |
| Other long-term liabilities | 88 | 83 |
| Total liabilities | 91,346 | 94,131 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of September 30, 2025, and December 31, 2024 | — | — |
| Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,781,976 and 6,525,887 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 839,331 | 824,780 |
| Accumulated other comprehensive loss | (612) | (228) |
| Accumulated deficit | (718,297) | (655,116) |
| Total stockholders’ equity | 120,422 | 169,436 |
| Total liabilities and stockholders’ equity | $211,768 | $263,567 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.